UPM’s GrowDex hydrogel helps with this process by creating an environment similar to the humanbody for the cells. Examining samples in 3D rather than conventional 2D allows researchers to recreatethe way they grow in the body rather than on a flat, two-dimensional surface. “GrowDex is inert,meaning there is nothing extra in it that would disturb the analysis of the cells – it is essentially nanocelluloseand water. The hydrogel surrounds the cell and replicates the three-dimensional cellularenvironment found in the human body,” Mikkonen says.

GrowDex keeps the cells suspended in their natural formation, meaning researchers can examine them in a 3D state as opposed to on 2D surface. This allows experts to experiment with different drug treatments, offering the patient the best chance of recovery. The cells, now surrounded and held in place by GrowDex, are transferred to an incubator (in the cover photo), giving Piia Mikkonen and her research team the necessary tools to examine the samples and determine the best treatment plan.
This is only the beginning for this treatment approach, which is being spearheaded by Finnish research. “At the moment, personalised medicine studies using GrowDex are focused on a specific range of diseases, but there is no reason why they cannot be advanced to include other aspects of medicine in the medium-term. I firmly believe that this is the future of medical treatment; however, the only question now is over who will pay for its universal rollout,” says Mikkonen.
TextCraig Houston
Photography Katariina Salmi